Abstract: The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
Type:
Grant
Filed:
March 27, 2020
Date of Patent:
December 13, 2022
Assignee:
Newgen Therapeutics, Inc.
Inventors:
Wang Shen, Aimin Zhang, Jack Maung, Xiaoling Zheng
Abstract: The invention provides quinazoline-7-ether derivatives, particularly 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives that are inhibitors of the receptor protein tyrosine kinases (RTK). The compounds are useful in the treatment of diseases and disorders where RTK activity is implicated such as a hyperproliferative diseases (e.g., cancer). Also provided are methods of preparation of the quinazoline derivatives and methods of use as therapeutic agents alone or in a drug combination.
Type:
Grant
Filed:
May 17, 2012
Date of Patent:
November 17, 2015
Assignee:
NewGen Therapeutics, Inc.
Inventors:
Wang Shen, Wei Xiao, Jack Maung, Aimin Zhang, Xiaoling Zheng, Zhenzhong Wang, Qingming Guo, Yingguang Li
Abstract: The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
Type:
Grant
Filed:
March 2, 2012
Date of Patent:
July 28, 2015
Assignee:
NewGen Therapeutics, Inc.
Inventors:
Wang Shen, Aimin Zhang, Jack Maung, Xiaoling Zheng
Abstract: Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.
Type:
Grant
Filed:
July 2, 2010
Date of Patent:
March 24, 2015
Assignee:
Newgen Therapeutics, Inc.
Inventors:
Wang Shen, Aimin Zhang, Junfa Fan, Xiaoling Zheng
Abstract: The invention provides quinazoline-7-ether derivatives, particularly 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives that are inhibitors of the receptor protein tyrosine kinases (RTK). The compounds are useful in the treatment of diseases and disorders where RTK activity is implicated such as a hyperproliferative diseases (e.g., cancer). Also provided are methods of preparation of the quinazoline derivatives and methods of use as therapeutic agents alone or in a drug combination.
Type:
Application
Filed:
May 17, 2012
Publication date:
August 7, 2014
Applicant:
Newgen Therapeutics, Inc.
Inventors:
Wang Shen, Wei Xiao, Jack Maung, Aimin Zhang, Xiaoling Zheng, Zhenzhong Wang, Qingming Guo, Yingguang Li
Abstract: The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.
Type:
Application
Filed:
May 31, 2012
Publication date:
August 7, 2014
Applicant:
NewGen Therapeutics, Inc.
Inventors:
Wang Shen, Jack Maung, Aimin Zhang, Xiaoling Zheng
Abstract: The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
Type:
Application
Filed:
March 2, 2012
Publication date:
May 8, 2014
Applicant:
Newgen Therapeutics, Inc.
Inventors:
Wang Shen, Aimin Zhang, Jack Maung, Xiaoling Zheng